Sage Journals: Discover world-class research

Abstract

Background:

The fourth universal definition of myocardial infarction requires an increase or decrease in cardiac troponin for the classification of non-ST-segment elevation myocardial infarction. We sought to determine whether the characteristics, management, and outcomes of patients admitted with non-ST-segment elevation myocardial infarction differ by the initial biomarker pattern.

Methods:

We identified patients in the Atherosclerosis Risk in Communities Surveillance Study admitted with chest pain and an initially elevated cardiac troponin I, who presented within 12 hours of symptom onset and were classified with non-ST-segment elevation myocardial infarction. A change in cardiac troponin I required an absolute difference of at least 0.02 ng/mL on the first day of hospitalization, prior to invasive cardiac procedures.

Results:

A total of 1926 hospitalizations met the inclusion criteria, with increasing cardiac troponin I more commonly observed (78%). Patients with decreasing cardiac troponin I were more often black (45% vs. 35%) and women (54% vs. 40%), and were less likely to receive non-aspirin antiplatelets (44% vs. 63%), lipid-lowering agents (62% vs. 80%), and invasive angiography (38% vs. 64%). Inhospital mortality was 3%, irrespective of the cardiac troponin I pattern. However, patients with decreasing cardiac troponin I had twice the 28-day mortality (12% vs. 5%; P=0.01). Fatalities within 28 days were more often attributable to non-cardiovascular causes in those with decreasing versus increasing cardiac troponin I (75% vs. 38%; P=0.01).

Conclusion:

Patients presenting with chest pain and an initially elevated cardiac troponin I which subsequently decreases are less often managed by evidence-based therapies and have greater mortality, primarily driven by non-cardiovascular causes. Whether associations are attributable to type 2 myocardial infarction or a subacute presentation merits further investigation.

Keywords

Non ST-segment elevation myocardial infarction cardiac troponin epidemiology outcomes

Get full access to this article

View all access options for this article.

References

Apple

Jesse

Newby

et al .; National Academy of Clinical Biochemistry, IFCC Committee for Standardization of Markers of Cardiac Damage. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007; 115: e352–e355.

Missov

Calzolari

Pau

Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96: 2953–2958.

Thygesen

Alpert

Jaffe

et al . Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American HeartAssociation (AHA)/World Heart Federation (WHF) TaskForce for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 2018; 25285. DOI:10.1016/j.jacc.2018.08.1038.

Biener

Mueller

Vafaie

et al . Diagnostic performance of rising, falling, or rising and falling kinetic changes of high-sensitivity cardiac troponin T in an unselected emergency department population. Eur Heart J Acute Cardiovasc Care 2013; 2: 314–322.

Horwich

Patel

MacLellan

et al . Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833–838.

Kim

Martinez

Faraday

et al . Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002; 106: 2366–2371.

The National Heart Lung and Blood Institute. Biologic Specimen and Data Repository Information Coordinating Center. https://biolincc.nhlbi.nih.gov/home/ (accessed 2 December 2018).

White

Folsom

Chambless

et al . Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years’ experience. J Clin Epidemiol 1996; 49: 223–233.

Rosamond

Chambless

Heiss

et al . Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987–2008. Circulation 2012; 125: 1848–1857.

10.

Myerson

Coady

Taylor

et al .; ARIC Investigators. Declining severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2009; 119: 503–514.

11.

Rosamond

Chambless

Sorlie

et al . Trends in the sensitivity, positive predictive value, false-positive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987–2000. Am J Epidemiol 2004; 160: 1137–1146.

12.

The Atherosclerosis Risk in Communities Study. Surveillance Component Procedures Manual of Operations. https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Manual3_Ver%206.6_20151112_0.pdf (accessed 29 March 2019).

13.

Roe

Peterson

et al . Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. Arch Intern Med 2005; 165: 1870–1876.

14.

Mansournia

Altman

DG.

Inverse probability weighting. BMJ 2016; 352: i189.

15.

Amsterdam

Wenger

Brindis

et al ,; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: e344–e426.

16.

Zhang

KF.

What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690–1691.

17.

Anand

Xie

Mehta

et al .; CURE Investigators. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1845–1851.

18.

Rathore

Wang

Radford

et al . Sex differences in cardiac catheterization after acute myocardial infarction: the role of procedure appropriateness. Ann Intern Med 2002; 137: 487–493.

19.

Arora

Stouffer

Kucharska-Newton

et al . Fifteen-year trends in management and outcomes of non-ST-segment-elevation myocardial infarction among black and white patients: the ARIC Community Surveillance Study, 2000–2014. J Am Heart Assoc 2018; 7: e010203.

20.

Rose

Foraker

Heiss

et al . Neighborhood socioeconomic and racial disparities in angiography and coronary revascularization: the ARIC surveillance study. Ann Epidemiol 2012; 22: 623–629.

21.

Bhatt

Roe

Peterson

et al .; CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096–2104.

22.

Zia

Goodman

Peterson

et al . Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. Can J Cardiol 2007; 23: 1073–1079.

23.

Steg

Dabbous

Feldman

et al .; Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109: 494–499.

24.

Malmberg

Yusuf

Gerstein

et al . Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014–1019.

25.

Thygesen

Alpert

White

; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe

Apple

Galvani

et al . Universal definition of myocardial infarction. Circulation 2007; 116: 2634–2653.

26.

Sandoval

Smith

Thordsen

et al . Supply/demand type 2 myocardial infarction: should we be paying more attention? J Am Coll Cardiol 2014; 63: 2079–2087.

27.

McCarthy

Vaduganathan

Januzzi

JL . Type 2 myocardial infarction – diagnosis, prognosis, and treatment. JAMA 2018; 320: 433–434.

28.

Starnberg

Jeppsson

Lindahl

et al . Revision of the troponin T release mechanism from damaged human myocardium. Clin Chem 2014; 60: 1098–1104.

29.

International Federation of Clinical Chemistry and Laboratory Medicine. Calculating Serial Change Values (Delta) for High-sensitivity Cardiac Troponin Assays. www.ifcc.org/media/259735/201405_TF_CB_IFCC_practice%20Extended%20document.pdf (accessed 2 December 2018).

30.

Hritani

Jan

Schleis

et al . Clinical features and prognosis of type 2 myocardial infarction in acutely decompensated diabetic patients. Am J Med 2018; 131: 820–828.

31.

Arora

Strassle

Qamar

et al . Impact of type 2 myocardial infarction (MI) on hospital-level MI outcomes: implications for quality and public reporting. J Am Heart Assoc 2018; 7: 008661.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.28 MB

Outcomes of decreasing versus increasing cardiac troponin in patients admitted with non-ST-segment elevation myocardial infarction: the Atherosclerosis Risk in Communities Surveillance Study

Abstract

Background:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material